Northstar Neuroscience, a Seattle medical device company, said today the FDA has given conditional approval to run a second study of its brain-stimulation device against depression. Northstar (NASDAQ: [[ticker:NSTR]]) said it plans to start enrolling the first of 24 patients in the study, called Prospect II, before the end of the year. Preliminary results should be available in the second half of 2009. The company switched its strategy this year to focus on depression after a pivotal study failed to restore arm movement for patients recovering from strokes.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
